Clinical trials: Pharmacodynamics
Hyperphosphatemia
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
This study is a randomized study designed as a 2x2 cross-over in two periods (Period 1 and Period 2) to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of EOS789 in patients with chronic kidney…
- Trial name
- NCT02965053
- Testing
- EOS789, Renvela
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Chugai Pharmaceutical
Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD.
- Trial name
- SUSPIRE-1 (NCT06533553)
- Testing
- Dexpramipexole Dihydrochloride
- Where
- 23 sites in United States
- Volunteers
- 30 people
- Sponsor
- Areteia Therapeutics
Cancer
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
The purpose of this study is to determine whether the MEK inhibitor and the AKT inhibitor can be given in combination and if the combination is effective treatment for patients with solid tumors, including breast cancer and…
- Trial name
- NCT01476137
- Testing
- GSK1120212, GSK2110183
- Where
- 2 sites in United States
- Volunteers
- 335 people
- Sponsor
- GlaxoSmithKline
Adult Onset Still's Disease
A Study to Evaluate Camoteskimab in Participants With Still's Disease
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
- Trial name
- NCT04752371
- Testing
- Camoteskimab (CERC-007, AVTX-007, AEVI-007)
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 5 people
- Sponsor
- Apollo Therapeutics Ltd
Chronic Inducible Urticaria
A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
This is an open-label, single ascending dose Phase 1b/2a trial to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with Cold Urticaria (ColdU) or Symptomatic…
- Trial name
- SPOTLIGHT (NCT06353971)
- Testing
- Briquilimab
- Where
- 5 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Jasper Therapeutics, Inc.
Asthma
A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists
This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled…
- Trial name
- NCT05110976
- Testing
- AZD8630
- Where
- 29 sites in United States, Germany and 1 more
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.
- Trial name
- NCT02306876
- Testing
- PF-06412562 3mg BID, PF-06412562 15mg BID
- Where
- 3 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study of LY3006072 in Healthy Participants
The purpose of this study is to evaluate how safe LY3006072 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body…
- Trial name
- NCT01640249
- Testing
- LY3006072
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pulmonary Hypertension
Pharmacokinetics and Pharmacdynamics of Sildenafil
The study is being done to investigate what happens to sildenafil in the body and how long it takes to get rid of this drug. Understanding how long the drug stays in the body and how it is changed by the body will help doctors…
- Trial name
- NCT00718185
- Testing
- Obtain blood specimens
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Children's Hospital of Philadelphia
Hypotension
Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room
Sodium nitroprusside (SNP) has been approved for control of blood pressure in adults, yet there are no controlled studies in children.
- Trial name
- NCT00135668
- Testing
- Nitroprusside
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- The Emmes Company, LLC
Sporadic Inclusion Body Myositis
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis
- Trial name
- NCT01423110
- Testing
- BYM338
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation
The purpose of this study, called MOVE-PD, is to investigate how individuals with Parkinson's disease (PD) and chronic constipation (CC) respond to RM-131 as compared to placebo.
- Trial name
- MOVE-PD (NCT01955616)
- Testing
- RM-131
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Motus Therapeutics, Inc.
AD
A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this Phase 1 study is to evaluate the safety and tolerability of a new investigational drug called SSGJ-716 in healthy adults and in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07693738
- Testing
- SSGJ-716
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Myeloid Leukemia in Children
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
- Trial name
- CHIP-AML22/Q (NCT06262438)
- Testing
- Quizartinib, Etoposide, Dexrazoxane
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus, Coronary Artery Disease
Aspirin Dosing in Diabetic Patients
Since diabetic platelets are characterized by an enhanced turnover rate, it may be hypothesized that an increase in the frequency, rather than the dose, of drug administration may be a more effective strategy to inhibit platelet…
- Trial name
- NCT01201785
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Anesthesia, Sedation
A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486
This is a Phase I, single-center, open-label, randomized,two-way crossover, propofol-controlled, two-stage study evaluating the safety and pharmacokinetics/pharmacodynamics of IV maintenance dose after an initial dose and IV…
- Trial name
- NCT03745625
- Testing
- HSK3486, Propofol
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Healthy Participants
A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.
To evaluate the safety and tolerability of single and multiple ascending doses of oral RO7020531 in Chinese healthy participants.
- Trial name
- NCT03530917
- Testing
- RO7020531
- Where
- Hong Kong
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hypercholesterolemia
A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects
JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody; This is a phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single…
- Trial name
- NCT04197817
- Testing
- JS002
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Attention Deficit Disorder With Hyperactivity
The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD
The goal of this clinical trial is to compare in the pk/pd profiles of magisterial dexamfetamine and Tentin in adults with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- DAVE (NCT05621174)
- Testing
- Dexamfetamine
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.